For men with only bone mets Xofigo will target and treat these mets.Īfter this discussion, we do need to add some additional complications. If you do not express PSMA, Pluvicto will not treat your mets. If you do express PSMA, verified by a positive PSMA scan, then Pluvicto can treat both bone and soft tissue mets. Pluvicto targets PSMA, but not all men express the protein PSMA. Pluvicto and Xofigo have different targeting abilities. One treatment is not better than the other they are different. Xofigo does not require the presence of PSMA to successfully treat the bone metastases. So, Xofigo specifically goes to the bones delivering the radiation treatment to the mets in the bones Xofigo will not treat soft tissue mets. Xofigo mimics calcium, and calcium goes to bones.
The radioactive component or the actual treatment drug is lutetium-177. This protein, PSMA, is present in both bone and soft tissue prostate cancer mets, in around 80 to 90 percent of men. In Pluvicto (177Lu-PSMA-617) the delivery vehicle (ligand) is PSMA-617 (aka, vipivotide tetraxetan), a drug that latches onto a protein called PSMA that is often found at high levels on the surface of prostate cancer cells. Pluvicto has two components, a drug that delivers, or targets, the therapy to the cancer cells and a radioactive particle that treats or destroys the cancer cells after they have been delivered to the mets. Making a sound decision can be helped by understanding the mode of action and the limits of each treatment. There is no simple answer, and the answer is not the same for each of us. Several men have asked us if they are better off having 177Lu-PSMA-617 (Pluvicto) a radiopharmaceutical drug that treats PSMA positive metastases or Xofigo, a radiopharmaceutical drug that treats bone metastases.
0 kommentar(er)
